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Background
In endothelial dysfunction, signalling by nitric oxide
(NO) is impaired because of the oxidation and subse-
quent loss of the soluble guanylyl cyclase (sGC) haem [1].
The sGC activator 4-[((4-carboxybutyl){2-[(4-phenethyl-
benzyl)oxy]phenethyl}amino)methyl [benzoic]acid
(BAY 58-2667) is a haem-mimetic able to bind with high
affinity to GC when the native haem (the NO binding
site) is removed and it also protects sGC from ubiquitin-
triggered degradation [2-4]. Here we investigate whether
this protection is a unique feature of BAY 58-2667 or a
general characteristic of haem-site ligands such as the
haem-independent sGC activator 5-chloro-2-(5-chloro-
thiophene-2-sulphonylamino-N-(4-(morpholine-4-
sulphonyl)-phenyl)-benzamide sodium salt (HMR
1766), the haem-mimetic Zn-protoporphyrin IX (Zn-
PPIX) or the haem-dependent sGC stimulator 5-cyclopro-
pyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-
yl]-pyrimidin-4-ylamine (BAY 41-2272).
Experimental approach
The sGC inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]quinoxa-
lin-1-one (ODQ) was used to induce oxidation-induced
degradation of sGC. Activity and protein levels of sGC
were measured in a Chinese hamster ovary cell line as well
as in primary porcine endothelial cells. Cells expressing
mutant sGC were used to elucidate the molecular mecha-
nism underlying the effects observed.
Results
Oxidation-induced sGC degradation was prevented by
BAY 58-2667 and Zn-PPIX in both cell types. In contrast,
the structurally unrelated sGC activator, HMR 1766, and
the sGC stimulator, BAY 41-2272, did not protect. Simi-
larly, the constitutively haem-free sGC mutant β1H105F
was stabilized by BAY 58-2667 and Zn-PPIX.
Conclusion
The ability of BAY 58-2667 not only to activate but also to
stabilize oxidized/haem-free sGC represents a unique
example of bimodal target interaction and distinguishes
this structural class from non-stabilizing sGC activators
and sGC stimulators such as HMR 1766 and BAY 41-2272
respectively.
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